FIELD: medicine.
SUBSTANCE: what is described is a DR5 antibody or its antigen-binding fragment including heavy and light chains wherein said antibody contains at least one substitute in the sequence of the full-length antibody 16E2. What is presented is a pharmaceutical composition for treating cancer containing the described antibody. What is offered is a method for apoptosis induction involving action of the described antibody or its antigen-binding fragment on malignant mammal cells. What is offered is a method for tumour treatment involving the introduction of an effective amount of the described antibody or its antigen-binding fragment to a mammal.
EFFECT: invention extends the range of products for cancer treatment.
45 cl, 37 dwg, 13 tbl, 10 ex
